SRNE News and Press, Sorrento Therapeutics Inc. From 01/20/21

Sorrento Therapeutics, Inc. (SRNE) B. Riley Virtual Oncology Conference Call January 20, 2021 14:30 ET Company Participants Henry Ji - Chairman, President & Chief Executive Officer Conference Call Participants Mayank Mamtani - B. Riley Presentation Mayank Mamtani Greetings. Thanks everyon...

Sorrento Therapeutics (SRNE) will present preliminary results from an ongoing SARS-CoV-2 mutation surveillance program on Thursday, January 21 at 2:45 PM PST. 'An Antibody’s Story: A Journey from Phage Library to an IND of STI 1499,' will be discussed.The company says data provide evid...

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation surveillance program for its neutralizing antibodies currently in clinical and pre-clinical devel...

SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: Fireside chat during the B. Riley Securities Oncology Investor Conference ...

Looking For The Best Biotech Stocks To Watch? 3 To Consider Biotech stocks have been and still are on a tear in the stock market now. The industry as a whole is currently under the microscope of many investors. Obviously, this is due to the coronavirus pandemic that continue...

The Nasdaq Composite (NASDAQINDEX: ^IXIC) has been doing very well in recent months, rising to set dozens of new record closing highs. On Friday, Nasdaq investors decided it was time for a pause, as the benchmark fell about half a percent just before 3 p.m. EST. However, some in...

After a ~9.9% rise in value yesterday, Sorrento Therapeutics (SRNE) has added another ~8.9% so far today, and an analyst from H.C. Wainwright estimates a price target of ~$30 for the stock, implying a ~275.0% upside to yesterday’s close.The analyst Ram Selvaraju pro...

Today, we revisit Sorrento Therapeutics for the first time in eight months. The investment recommendation we made at that time is on the verge of netting an approximate 90% return. We update our investment thesis and the current way we would play this small biotech name in the par...

SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: H.C. WAINWRIGHT BIOCONNECT 2021 January 11-14, 2021 (Virtual Conference) ...

The Robinhood app is popular among millennial investors. And as the Covid-19 pandemic focused attention on the biotech industry last year, many young investors rushed to bet on the sector. Though market hype has lately helped usher many biotech stocks onto the Robinhood 100 list (of most popu...